News Release Issued: Dec 11, 2015 (8:00am EST)
Post# of 223
Posted On: 12/11/2015 8:10:01 AM
News
Release Issued: Dec 11, 2015 (8:00am EST)
Study Shows Safety of BioPharmX Topical Formulation
Research suggests BPX-01 topical minocycline could be more effective in treatment of acne than other topical treatments
MENLO PARK, Calif., Dec. 11, 2015 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, announced today that research being presented at ASCB 2015 in San Diego shows its unique formulation of minocycline known as BPX-01 may offer a breakthrough in acne treatment because it can safely deliver the antibiotic to the layer of skin where the condition develops.
BioPharmX (BPMX)
Study findings will be presented Monday afternoon at the annual gathering of the American Society of Cell Biology.
Session: Defining Therapeutic Targets and New Therapeutics 2
Time: 1:30pm to 3:00pm
Location: ASCB Learning Center, Exhibit Halls D-H
BPX-01 is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline, the antibacterial and anti-inflammatory medicine most commonly prescribed to treat acne because it has a lower resistance rate than other antibiotics.
Topical acne medications available today penetrate the top layer of skin with less effective antibiotics. However, minocycline is generally prescribed as an oral medication due to the lack of availability of effective topical medications. High doses of oral minocycline are associated with various side effects that can discourage compliance.
"Our preliminary findings in animals and in vitro human skin indicate that minocycline delivered by BPX-01 is safely absorbed into the skin, reaching the epidermis and the pilosebaceous unit where acne develops," said Kin F. Chan, Ph.D., executive vice president of research and development at BioPharmX Corporation. "The studies clearly indicate that all doses of BPX-01 were found to be safe and nontoxic for topical use, virtually eliminating risk of undesirable side effects."
The BioPharmX research also found that the hydrophilic BPX-01 formulation distributes evenly, is not sticky and does not occlude or irritate the skin, an advantage in the treatment of acne.
The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting 40 million to 50 million Americans at any given moment. The disease can cause permanent scarring, low self-esteem, depression and anxiety.
Release Issued: Dec 11, 2015 (8:00am EST)
Study Shows Safety of BioPharmX Topical Formulation
Research suggests BPX-01 topical minocycline could be more effective in treatment of acne than other topical treatments
MENLO PARK, Calif., Dec. 11, 2015 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, announced today that research being presented at ASCB 2015 in San Diego shows its unique formulation of minocycline known as BPX-01 may offer a breakthrough in acne treatment because it can safely deliver the antibiotic to the layer of skin where the condition develops.
BioPharmX (BPMX)
Study findings will be presented Monday afternoon at the annual gathering of the American Society of Cell Biology.
Session: Defining Therapeutic Targets and New Therapeutics 2
Time: 1:30pm to 3:00pm
Location: ASCB Learning Center, Exhibit Halls D-H
BPX-01 is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline, the antibacterial and anti-inflammatory medicine most commonly prescribed to treat acne because it has a lower resistance rate than other antibiotics.
Topical acne medications available today penetrate the top layer of skin with less effective antibiotics. However, minocycline is generally prescribed as an oral medication due to the lack of availability of effective topical medications. High doses of oral minocycline are associated with various side effects that can discourage compliance.
"Our preliminary findings in animals and in vitro human skin indicate that minocycline delivered by BPX-01 is safely absorbed into the skin, reaching the epidermis and the pilosebaceous unit where acne develops," said Kin F. Chan, Ph.D., executive vice president of research and development at BioPharmX Corporation. "The studies clearly indicate that all doses of BPX-01 were found to be safe and nontoxic for topical use, virtually eliminating risk of undesirable side effects."
The BioPharmX research also found that the hydrophilic BPX-01 formulation distributes evenly, is not sticky and does not occlude or irritate the skin, an advantage in the treatment of acne.
The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting 40 million to 50 million Americans at any given moment. The disease can cause permanent scarring, low self-esteem, depression and anxiety.
(0)
(0)BioPharmX Corporation (BPMX) Stock Research Links
Scroll down for more posts ▼